Novasep to Build the World's Largest Chromatography Plant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novasep to Build the World's Largest Chromatography Plant


ePT--the Electronic Newsletter of Pharmaceutical Technology

Novasep announced that it will be investing EUR 30 million ($39 million) to build what will be the world’s largest chromatography plant for the production of large volumes of commercial APIs. The plant will be built on Novasep’s existing site in Mourenx, France, and is expected to be operational and validated within 18 months. According to the company’s press release, the new plant, designed by an in-house engineering team, will contain Varicol continuous chromatography systems with 1200-mm diameter columns operated at up to 70 bars. The plant will enable the production of a highly purified API from a complex mixture. In addition, the systems will integrate sophisticated solvent recovery systems for the recycling of 99.9% of solvents.

According to the press release, the chromatography plant is the third in a string of global investments by Novasep. The first was the opening of a 2000-m2 facility in Shanghai, China and the second was a EUR three million ($3.9 million) investment to expand the highly potent API manufacturing capabilities at Novasep’s facility in Le Mans, France. “Demand for Novasep’s advanced, purification-based manufacturing capabilities in the life-science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third and largest global plant expansion in 2012,” said Patrick Glaser, president and CEO of Novasep, in the release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here